KalVista Pharmaceuticals is advancing towards the potential commercial launch of sebetralstat, an investigational oral treatment for hereditary angioedema (HAE) attacks. The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for sebetralstat, setting a Prescription Drug User Fee Act (PDUFA) goal date of June 17, 2025. This development marks a significant step forward in providing a novel oral option for HAE patients.
Financial Runway and Strategic Investments
KalVista has secured a strong financial position, reporting pro forma cash and cash equivalents of $292.2 million as of October 31, 2024. This includes $160 million raised through a combination of synthetic royalty financing and equity offerings. The company anticipates that these funds will provide sufficient runway into the second half of 2027, supporting ongoing clinical development and pre-commercial activities. Research and development expenses for the quarter were $16.6 million, while general and administrative expenses increased to $29.2 million due to pre-commercial planning for sebetralstat.
Regulatory Submissions and Global Expansion
In addition to the FDA acceptance, KalVista has submitted Marketing Authorization Applications (MAAs) to regulatory authorities in the United Kingdom, Switzerland, Australia, and Singapore through the Access Consortium framework. This collaborative approach aims to streamline the review process and expedite potential approvals across multiple countries. The European Medicines Agency (EMA) has also validated the MAA for sebetralstat, further expanding its potential global reach.
Clinical Data Highlights Efficacy and Patient Benefits
Recent presentations at the American College of Allergy, Asthma and Immunology and the HAEi Global Angioedema Forum showcased promising clinical data for sebetralstat. Phase 3 trial data indicated that early treatment with sebetralstat is correlated with shorter attack duration. A comparison of Phase 3 results for oral sebetralstat and pivotal trial results of IV recombinant C1-inhibitor for on-demand treatment of HAE attacks showed no significant differences in time to symptom relief. Furthermore, data presented at the HAEi Global Angioedema Forum highlighted the effectiveness of sebetralstat in reducing anxiety during HAE attacks, underscoring the importance of having an accessible oral treatment option.
Addressing Unmet Needs in HAE Treatment
Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of severe swelling. Current treatment options often involve injectable therapies, which can be associated with anxiety and reduced treatment adherence. Sebetralstat, if approved, has the potential to be the first oral on-demand treatment for HAE attacks, offering a more convenient and patient-friendly alternative. Ben Palleiko, Chief Executive Officer of KalVista, stated, "With six marketing authorization applications filed to date and the first potential approval expected next June, we remain focused on achieving our goal of making sebetralstat available to people living with HAE globally."
